Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial
Authors:
- Michael BrundageMBMichael Brundage
- Matthew R. SydesMSMatthew R. Sydes
- Wendy R. ParulekarWPWendy R. Parulekar
- Padraig WardePWPadraig Warde
- Richard CowanRCRichard Cowan
- Andrea BezjakABAndrea Bezjak
- Peter KirkbridePKPeter Kirkbride
- Matthew ParliamentMPMatthew Parliament
- Clare MoynihanCMClare Moynihan
- Jean-Paul BaharyJBJean-Paul Bahary
- Mahesh K.B. ParmarMPMahesh K.B. Parmar
- Karen SandersKSKaren Sanders
- 1 July 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (19) , 2151-2157
Abstract
Purpose: The NCIC CTG PR3/MRC PR07 randomized phase III trial compared androgen-deprivation therapy (ADT) alone versus ADT with radiotherapy (RT) for patients with locally advanced prostate cancer. This article reports the health-related quality-of-life (HRQOL) outcomes of this trial. Patients and Methods: A total of 1,205 patients were randomly allocated to either ADT alone or ADT with RT. HRQOL was assessed at baseline and every 6 months thereafter using the European Organisation for Research and Treatment of Cancer Core Questionnaire and a prostate cancer–specific checklist or the Functional Assessment of Cancer Therapy–Prostate questionnaire. Mean changes from baseline scores for five function domains and nine symptom domains were analyzed as those most relevant to ADT and RT. The proportions of patients with improved, stable, or worsened HRQOL scores according to instrument-specific minimal important differences were calculated. Results: Baseline questionnaires were completed by 1,028 patients (88%). At 6 months, RT had a statistically significant impact on mean score for bowel symptoms (P = .02), diarrhea (P < .001), urinary function (P = .003), and erectile dysfunction (P = .008); by 3 years, however, there were no significant between-group differences in any domain. Generalized linear mixed modeling revealed no significant between-arm differences in any of the function scales but showed significant deterioration in both arms over time for Functional Assessment of Cancer Therapy–Prostate total score, treatment outcome index, and physical and functional well-being. Conclusion: The addition of RT to ADT for patients with locally advanced prostate cancer significantly improved overall survival and had only modest and transient negative impact on relevant domains of HRQOL.Keywords
This publication has 14 references indexed in Scilit:
- Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With RadiotherapySeminars in Radiation Oncology, 2013
- Reporting of Patient-Reported Outcomes in Randomized TrialsJAMA, 2013
- International Variation in Prostate Cancer Incidence and Mortality RatesEuropean Urology, 2012
- Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the LiteratureCancer Investigation, 2012
- Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trialThe Lancet, 2011
- Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials GroupEuropean Journal of Cancer, 2005
- Men, women, gender and cancerEuropean Journal of Cancer Care, 2002
- Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology, 1998
- Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrumentUrology, 1997
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993